Sales of the company's top-selling drug, the antipsychotic Zyprexa, fell 3 percent to $1.2 billion. Total revenue rose 3 percent to $5.29 billion, reflecting higher volume and prices. Revenue was also helped by contributions from Erbitux as a result of Eli Lilly's acquisition of ImClone.
For the full year, the Indianapolis company says it now expects to earn $4.20 to $4.30 per share, versus a prior range of $4 to $4.25 per share.
